Case Report: Treatment of Hypertrophic Cardiomyopathy With Stereotactic Body Radiotherapy

Frontiers in Medicine

Medicine

Yan Tang¹  Longzihui Xiao²  Yingzhe Zhang²  Yuefei Liu²  Taili Chen³  Zhuyuan Ding⁴  Jiayi Liu⁴  Enhua Xiao⁴  Minping Zhang⁵ 

[1] Department of Medical Record, The Second Xiangya Hospital of Central South University, Changsha, China;Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China;Department of Oncology, Xiangya Hospital of Central South University, Changsha, China;Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, China;Department of Ultrasound Diagnosis, The Second Xiangya Hospital of Central South University, Changsha, China;

关键词: radiosurgery;    quality of life;    hypertrophic cardiomyopathy;    stereotactic body radiotherapy (SBRT);    radiotherapy;    four-dimensional computed tomography (4D-CT);   

DOI  :  10.3389/fmed.2022.799310

 received in 2021-10-21, accepted in 2022-05-16,  发布年份 2022

来源: Frontiers

【 摘 要 】

Patients with hypertrophic cardiomyopathy (HCM), which is characterized by left ventricular hypertrophy, is usually treated with medications such as calcium channel blockers or beta-blockers and invasive treatments such as transcatheter alcohol septal ablation, percutaneous radiofrequency ablation, or heart transplantation. However, non-invasive methods have not been employed for the management of patients with HCM. A 71-year-old male who presented with occasional chest pain for approximately 2 months and had been diagnosed with HCM since he was 39 years old due to occasional fainting was treated with a novel method for HCM using stereotactic body radiotherapy (SBRT). The administration of 25 Gy of radiation as one fraction led to an improvement in his quality of life. No toxicity occurred during or immediately after the treatment. Our observations suggest that SBRT may be a reasonable treatment approach for patients with HCM who are not suitable for surgery.

【 授权许可】

Unknown   
Copyright © 2022 Xiao, Liu, Zhang, Liu, Tang, Zhang, Ding, Xiao and Chen.